Allogeneic bone marrow transplantation for thalassemia in Taiwan: factors associated with graft failure

Area of Science:

• Hematology
• Pediatric Hematology
• Transplantation Medicine

Background:

• Thalassemia is a serious inherited blood disorder requiring lifelong treatment.
• Allogeneic bone marrow transplantation (BMT) offers a potential cure for thalassemia.
• Early BMT outcomes in pediatric thalassemia patients were evaluated.

Purpose of the Study:

• To assess the efficacy and safety of allogeneic bone marrow transplantation (BMT) in pediatric thalassemia patients.
• To identify major causes of morbidity and mortality associated with BMT in this population.

Main Methods:

• Retrospective analysis of 14 pediatric thalassemia patients undergoing allogeneic BMT between 1984 and 1987.
• Preconditioning regimens included oral busulfan and intravenous cyclophosphamide, with or without irradiation.
• Evaluation of engraftment, graft failure, chimerism, complications, and survival rates.

Main Results:

• Overall survival rate was 64% (9/14 patients) with 1-4 years of follow-up.
• Major causes of mortality included intracranial hemorrhage (2), sepsis (2), and graft-versus-host disease (1).
• Two patients with maternal transplants failed to engraft but showed autologous recovery; sibling marrow recipients had variable engraftment and chimerism.

Conclusions:

• Allogeneic BMT can be a curative option for thalassemia, but significant risks exist.
• Infection, graft-versus-host disease, and hemorrhage are critical challenges in BMT for thalassemia.
• Prior multiple transfusions and sex-mismatched transplants may negatively impact outcomes; autologous recovery is common after engraftment failure.